Evaluation of Bax and Bak Gene Mutations and Expression in Breast Cancer

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2014 Mar 28

PMID 24672785

Citations 9

Authors

Naglaa Mohamed Kholoussi

Sobhy E H El-Nabi

Nora Nassef Esmaiel

Naser Mohamed Abd El-Bary

Ahmed F El-Kased

Affiliations

Soon will be listed here.

Abstract

Genetic analyses have provided evidence to suggest that Bax and Bak are the essential genes for apoptosis in mammalians cells. This study aimed to search for biomarkers in breast cancer to be used as prognostic markers for the disease. The Bak and Bax genes expressions were analyzed in 23 breast cancer patients by RT-PCR technique. SSCP technique was used to detect the mobility of the abnormal fragment in Bak exon 4. PCR for Bax promoter was digested with Tau 1 restriction enzyme to identify a single polymorphism G(-248)A. The expression of Bak gene is related to several clinical factors of breast cancer. The analysis of Bax RNA showed 4 isoforms of Bax with different distributions in the normal and tumor tissues. These isoforms were Bax α , d, δ , and ζ . Exon 4 had a normal pattern in all cases of breast cancer. There was a statistically significant difference in the frequency distribution of the G(-248)A genotypes in the breast cancer tissues with grade 3+high, T2 stage, lobular +other, and PR -ve subgroups. In this study, Bak expression seems to lead to development of breast cancer and affects the disease progression. Also, Bax d and Bax δ could be used as risk factor and biomarker for breast cancer with the distribution of G284A.

Citing Articles

In-Vitro Cytotoxicity, Apoptotic Property, and Gene Expression Changes Induced by Naringenin-7-O-Glucoside in Triple-Negative Breast Cancer.

James A, Jayaprakash S, Sundeep L Cureus. 2024; 16(4):e58634.

PMID: 38770462 PMC: 11104259. DOI: 10.7759/cureus.58634.

Analysis of the Polymorphisms and Expression Levels of the BCL2, BAX and c-MYC Genes in Patients with Ovarian Cancer.

Olbromski P, Bogacz A, Bukowska M, Kaminski A, Moszynski R, Pawlik P Int J Mol Sci. 2023; 24(22).

PMID: 38003498 PMC: 10671037. DOI: 10.3390/ijms242216309.

Box-Behnken design of thermo-responsive nano-liposomes loaded with a platinum(iv) anticancer complex: evaluation of cytotoxicity and apoptotic pathways in triple negative breast cancer cells.

Sedky N, Braoudaki M, Mahdy N, Amin K, Fawzy I, Efthimiadou E Nanoscale Adv. 2023; 5(19):5399-5413.

PMID: 37767043 PMC: 10521260. DOI: 10.1039/d3na00368j.

Association of XRCC3, XRCC4, BAX, and BCL-2 Polymorphisms with the Risk of Breast Cancer.

Ozoran E, Trabulus F, Erhan D, Batar B, Guven M Int J Breast Cancer. 2022; 2022:5817841.

PMID: 35320970 PMC: 8938079. DOI: 10.1155/2022/5817841.

High-resolution analysis of the conformational transition of pro-apoptotic Bak at the lipid membrane.

Sperl L, Ruhrnossl F, Schiller A, Haslbeck M, Hagn F EMBO J. 2021; 40(20):e107159.

PMID: 34523144 PMC: 8521305. DOI: 10.15252/embj.2020107159.

References

Miller S, Dykes D, Polesky H . A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16(3):1215. PMC: 334765. DOI: 10.1093/nar/16.3.1215. View

Ghayad S, Vendrell J, Bieche I, Spyratos F, Dumontet C, Treilleux I . Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. J Mol Endocrinol. 2008; 42(2):87-103. DOI: 10.1677/JME-08-0076. View

Tong Q, Zheng L, Wang L, Liu J, Qian W . BAK overexpression mediates p53-independent apoptosis inducing effects on human gastric cancer cells. BMC Cancer. 2004; 4:33. PMC: 481072. DOI: 10.1186/1471-2407-4-33. View

Pataer A, Fang B, Yu R, Kagawa S, Hunt K, McDonnell T . Adenoviral Bak overexpression mediates caspase-dependent tumor killing. Cancer Res. 2000; 60(4):788-92. View

Graber H, Friess H, Zimmermann A, Korc M, Adler G, Schmid R . Bak expression and cell death occur in peritumorous tissue but not in pancreatic cancer cells. J Gastrointest Surg. 1999; 3(1):74-80; discussion 81. DOI: 10.1016/s1091-255x(99)80012-2. View

Schinzel A, Kaufmann T, Schuler M, Martinalbo J, Grubb D, Borner C . Conformational control of Bax localization and apoptotic activity by Pro168. J Cell Biol. 2004; 164(7):1021-32. PMC: 2172067. DOI: 10.1083/jcb.200309013. View

Moshynska O, Sankaran K, Saxena A . Molecular detection of the G(-248)A BAX promoter nucleotide change in B cell chronic lymphocytic leukaemia. Mol Pathol. 2003; 56(4):205-9. PMC: 1187322. DOI: 10.1136/mp.56.4.205. View

Koda M, Kanczuga-Koda L, Reszec J, Sulkowska M, Famulski W, Baltaziak M . Expression of the apoptotic markers in normal breast epithelium, benign mammary dysplasia and in breast cancer. Folia Morphol (Warsz). 2004; 63(3):337-41. View

Kanduc D, Mittelman A, Serpico R, Sinigaglia E, Sinha A, Natale C . Cell death: apoptosis versus necrosis (review). Int J Oncol. 2002; 21(1):165-70. View

10.

Ghatan S, Larner S, Kinoshita Y, Hetman M, Patel L, Xia Z . p38 MAP kinase mediates bax translocation in nitric oxide-induced apoptosis in neurons. J Cell Biol. 2000; 150(2):335-47. PMC: 2180235. DOI: 10.1083/jcb.150.2.335. View

11.

Van de Casteele M, Kefas B, Ling Z, Heimberg H, Pipeleers D . Specific expression of Bax-omega in pancreatic beta-cells is down-regulated by cytokines before the onset of apoptosis. Endocrinology. 2001; 143(1):320-6. DOI: 10.1210/endo.143.1.8574. View

12.

Lahiri O, Harris S, Packham G, Howell M . p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia. Cancer Genet Cytogenet. 2007; 179(1):36-44. DOI: 10.1016/j.cancergencyto.2007.07.013. View

13.

Maia S, Nicholas Haining W, Ansen S, Xia Z, Armstrong S, Seth N . Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia. Cancer Res. 2005; 65(21):10050-8. DOI: 10.1158/0008-5472.CAN-05-1574. View

14.

Starczynski J, Pepper C, Pratt G, Hooper L, Thomas A, Milligan D . Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated. J Clin Oncol. 2005; 23(7):1514-21. DOI: 10.1200/JCO.2005.02.192. View

15.

Antonsson B, Montessuit S, Sanchez B, Martinou J . Bax is present as a high molecular weight oligomer/complex in the mitochondrial membrane of apoptotic cells. J Biol Chem. 2001; 276(15):11615-23. DOI: 10.1074/jbc.M010810200. View

16.

Xie T, Ho S, Ma O . High resolution single strand conformation polymorphism analysis using formamide and ethidium bromide staining. Mol Pathol. 1998; 50(5):276-8. PMC: 379648. DOI: 10.1136/mp.50.5.276. View

17.

Wei M, Zong W, Cheng E, LINDSTEN T, Panoutsakopoulou V, Ross A . Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001; 292(5517):727-30. PMC: 3049805. DOI: 10.1126/science.1059108. View

18.

Nuckel H, Frey U, Sellmann L, Bau M, Durig J, Duhrsen U . Bax gene G(-248)A promoter polymorphism and chronic lymphocytic leukemia: lack of association with incidence, disease stage and progression-free survival. Leukemia. 2006; 20(4):724. DOI: 10.1038/sj.leu.2404126. View

19.

Saxena A, Moshynska O, Sankaran K, Viswanathan S, Sheridan D . Association of a novel single nucleotide polymorphism, G(-248)A, in the 5'-UTR of BAX gene in chronic lymphocytic leukemia with disease progression and treatment resistance. Cancer Lett. 2002; 187(1-2):199-205. DOI: 10.1016/s0304-3835(02)00378-6. View

20.

Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K . Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res. 2006; 12(20 Pt 1):6116-24. DOI: 10.1158/1078-0432.CCR-06-0147. View